创模生物科技(北京)有限公司

CN / En

New Drug Development Services

New Drug Development Services

All categories
/
Antibody dependent cell-mediated cytotoxicity (ADCC)

Antibody dependent cell-mediated cytotoxicity (ADCC)

Description:
Description:
Information

Antibody-Dependent Cellular Cytotoxicity (ADCC)
NK cells play a pivotal role in innate immune responses, targeting cells marked by antibodies, such as tumor cells. Within the ADCC mechanism, antibodies bind to tumor cell antigens and come into contact with the activating Fc receptors of NK cells, thereby triggering their cytotoxic activity.
Target Cell Selection
Tumor Cell Lines: Suitable for a wide range of research and testing needs.
Primary Tumor Cells: More accurately simulating biological environments.
Genetically Engineered Cell Lines: Customized through genetic technology to meet specific research demands.
Effector Cell Sources
Commercially-sourced PBMCs: Standardized, suitable for most research.
Clinically-derived PBMCs: More targeted, suitable for specific scenarios.
NK92 Cell Line: Specially designed for NK cell research.
Analysis & Detection
Flow Cytometry: High precision differentiation of effector-target cells, providing accurate data for research.
Apoptotic Cell Percentage: Utilizing flow cytometry to accurately calculate the proportion of apoptotic cells, offering a direct assessment of ADCC effects.
Conclusion
Our ADCC platform offers a comprehensive set of research tools. Whether you're selecting the right cell source or conducting precise analysis and detection, we've got you covered. Begin your exploration of the potential role of ADCC in tumor therapy with us.

Validate the in vitro ADCC activity of Rituximab on Raji cells (with NK92 as effector cells).

  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司